ArticleInternational journal of clinical pharmacy2025

Real-world clinical outcomes of apalutamide versus abiraterone with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Eduardo Pons-Fuster et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.